News

Filter

Current filters:

GemzarPharmaceutical

1 to 9 of 14 results

Oncologists backing of combo products supporting cytotoxic market

13-05-2012

The popularity of combination therapies in the treatment of cancer is set to increase, which will help…

BiotechnologyGemzarMarkets & MarketingOncologyPharmaceuticalTaxotere

US oncologists see FOLFIRINOX as the most efficacious for advanced pancreatic cancer

07-03-2011

The majority of surveyed US oncologists (57%) identified FOLFIRINOX* as the most efficacious treatment…

Eli LillyFOLFIRINOXGemzarMarkets & MarketingNorth AmericaOncologyPharmaceutical

Increased uptake of FOLFIRINOX and launch of Abraxane will see dynamic change in treatment of pancreatic cancer patients

23-11-2010

Although the pancreatic cancer drug market will remain relatively flat through 2019 in the leading markets…

AbraxaneCelgeneEli LillyFOLFIRINOXGemzarMarkets & MarketingOncologyPharmaceutical

Pancreatic cancer has high rate of failures in late-stage clinical trials

03-06-2010

The pancreatic cancer market has fewer competitors than most cancer markets, despite being one of the…

Eli LillyGemzarMarkets & MarketingOncologyPharmaceuticalResearch

1 to 9 of 14 results

Back to top